Zynerba Pharmaceuticals, Inc.
ZYNEDelisted Oct 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621443
Zynerba Pharmaceuticals, Inc. was delisted on Oct 11, 2023; its insiders filed their last Form 4 on Oct 11, 2023; 43 institutions reported holding it in 13F filings for Q3 2023, worth $14.7M in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Zynerba Pharmaceuticals, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
ZYNE is no longer listed, and 13F filings after Q3 2023 list far fewer holders. See Q3 2023
- Institutional holders
- 1
- +1 vs. Q4 2023
- Shares held
- 12.7K
- +12.7K vs. Q4 2023
- Total value
- $16.2K
- +$16.2K vs. Q4 2023
- New holders
- 1
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZYNE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 1 | $16.2K |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 43 | $14.7M |
| Q2 2023 | 41 | $1.74M |
| Q1 2023 | 44 | $2.75M |
| Q4 2022 | 50 | $4.23M |
| Q3 2022 | 62 | $7.97M |
| Q2 2022 | 56 | $12.5M |
| Q1 2022 | 59 | $24.8M |
| Q4 2021 | 62 | $38.3M |
| Q3 2021 | 59 | $57.1M |
| Q2 2021 | 65 | $78.1M |
| Q1 2021 | 67 | $42.1M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Zynerba Pharmaceuticals, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| National Asset Management, Inc. | 12,732 | $16.2K | 0.00% | +12,732 | New |